Document is current
Any future updates will be listed below
-
Authors
Malme, Kristian Braathen
Berhe, Nega
Hunduma, Fufa
Desalegn, Hailemichael
Johannessen, Asgeir
-
Funding
Funding for this research was provided by:
Akershus University Hospital
- License Information
-
More Information
Article History
Received: 5 July 2025
Accepted: 1 August 2025
First Online: 30 September 2025
Declarations
:
: The study has received ethics approval from the regional ethics committee for south-eastern Norway (REK approval number: 656480, Feb 20, 2024) and from Ethiopian Health Authorities (number: 1712421863116, Dec 26 2023). All participants will have to provide written informed consent prior to study enrollment. Important modifications of the protocol will be communicated to relevant parties. At the end of the study, the local hospitals will assume responsability for the patients, to ensure sustainability. Supply of drugs and diagnostics will be the responsability of the Ethiopian Ministry of Health.
: All participants will have to provide written informed consent to participate in the study. Information regarding publication of results is included in the consent form.
: Kristian Braathen Malme report personal lecture fees from Gilead and GSK. The other authors having nothing to declare.
